63 research outputs found

    The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

    Get PDF
    EphB4 and its cognitive ligand ephrinB2 play an important role in embryonic vessel development and vascular remodeling. In addition, several reports suggest that this receptor ligand pair is also involved in pathologic vessel formation in adults including tumor angiogenesis. Eph/ephrin signaling is a complex phenomena characterized by receptor forward signaling through the tyrosine kinase of the receptor and ephrin reverse signaling through various protein–protein interaction domains and phosphorylation motifs of the ephrin ligands. Therefore, interfering with EphR/ephrin signaling by the means of targeted gene ablation, soluble receptors, dominant negative mutants or antisense molecules often does not allow to discriminate between inhibition of Eph/ephrin forward and reverse signaling. We developed a specific small molecular weight kinase inhibitor of the EphB4 kinase, NVP-BHG712, which inhibits EphB4 kinase activity in the low nanomolar range in cellular assays showed high selectivity for targeting the EphB4 kinase when profiled against other kinases in biochemical as well as in cell based assays. Furthermore, NVP-BHG712 shows excellent pharmacokinetic properties and potently inhibits EphB4 autophosphorylation in tissues after oral administration. In vivo, NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity in vitro or in cellular assays. The data shown here suggest a close cross talk between the VEGFR and EphR signaling during vessel formation. In addition to its established function in vascular remodeling and endothelial arterio-venous differentiation, EphB4 forward signaling appears to be an important mediator of VEGF induced angiogenesis since inhibition of EphB4 forward signaling is sufficient to inhibit VEGF induced angiogenesis

    Phosphatase and tensin homologue: a therapeutic target for SMA

    Get PDF
    Spinal muscular atrophy (SMA) is one of the most common juvenile neurodegenerative diseases, which can be associated with child mortality. SMA is caused by a mutation of ubiquitously expressed gene, Survival Motor Neuron1 (SMN1), leading to reduced SMN protein and the motor neuron death. The disease is incurable and the only therapeutic strategy to follow is to improve the expression of SMN protein levels in motor neurons. Significant numbers of motor neurons in SMA mice and SMA cultures are caspase positive with condensed nuclei, suggesting that these cells are prone to a process of cell death called apoptosis. Searching for other potential molecules or signaling pathways that are neuroprotective for central nervous system (CNS) insults is essential for widening the scope of developmental medicine. PTEN, a Phosphatase and Tensin homologue, is a tumor suppressor, which is widely expressed in CNS. PTEN depletion activates anti-apoptotic factors and it is evident that the pathway plays an important protective role in many neurodegenerative disorders. It functions as a negative regulator of PIP3/AKT pathway and thereby modulates its downstream cellular functions through lipid phosphatase activity. Moreover, previous reports from our group demonstrated that, PTEN depletion using viral vector delivery system in SMN delta7 mice reduces disease pathology, with significant rescue on survival rate and the body weight of the SMA mice. Thus knockdown/depletion/mutation of PTEN and manipulation of PTEN medicated Akt/PKB signaling pathway may represent an important therapeutic strategy to promote motor neuron survival in SMA

    Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses

    Get PDF
    (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates.We demonstrate that the VSVΔG/ZEBOVGP vaccine given 28 days pre-challenge either intranasally (IN), orally (OR), or intramuscularly (IM) protects non-human primates against a lethal systemic challenge of ZEBOV, and induces cellular and humoral immune responses. We demonstrated that ZEBOVGP-specific T-cell and humoral responses induced in the IN and OR groups, following an immunization and challenge, produced the most IFN-γ and IL-2 secreting cells, and long term memory responses.We have shown conclusively that mucosal immunization can protect from systemic ZEBOV challenge and that mucosal delivery, particularly IN immunization, seems to be more potent than IM injection in the immune parameters we have tested. Mucosal immunization would be a huge benefit in any emergency mass vaccination campaign during a natural outbreak, or following intentional release, or for mucosal immunization of great apes in the wild

    Synaptic AMPA receptor composition in development, plasticity and disease

    Get PDF

    MicroRNA Dysregulation in the Spinal Cord following Traumatic Injury

    Get PDF
    Spinal cord injury (SCI) triggers a multitude of pathophysiological events that are tightly regulated by the expression levels of specific genes. Recent studies suggest that changes in gene expression following neural injury can result from the dysregulation of microRNAs, short non-coding RNA molecules that repress the translation of target mRNA. To understand the mechanisms underlying gene alterations following SCI, we analyzed the microRNA expression patterns at different time points following rat spinal cord injury

    Exploration of Shared Genetic Architecture Between Subcortical Brain Volumes and Anorexia Nervosa

    Get PDF
    In MRI scans of patients with anorexia nervosa (AN), reductions in brain volume are often apparent. However, it is unknown whether such brain abnormalities are influenced by genetic determinants that partially overlap with those underlying AN. Here, we used a battery of methods (LD score regression, genetic risk scores, sign test, SNP effect concordance analysis, and Mendelian randomization) to investigate the genetic covariation between subcortical brain volumes and risk for AN based on summary measures retrieved from genome-wide association studies of regional brain volumes (ENIGMA consortium, n = 13,170) and genetic risk for AN (PGC-ED consortium, n = 14,477). Genetic correlations ranged from − 0.10 to 0.23 (all p > 0.05). There were some signs of an inverse concordance between greater thalamus volume and risk for AN (permuted p = 0.009, 95% CI: [0.005, 0.017]). A genetic variant in the vicinity of ZW10, a gene involved in cell division, and neurotransmitter and immune system relevant genes, in particular DRD2, was significantly associated with AN only after conditioning on its association with caudate volume (pFDR = 0.025). Another genetic variant linked to LRRC4C, important in axonal and synaptic development, reached significance after conditioning on hippocampal volume (pFDR = 0.021). In this comprehensive set of analyses and based on the largest available sample sizes to date, there was weak evidence for associations between risk for AN and risk for abnormal subcortical brain volumes at a global level (that is, common variant genetic architecture), but suggestive evidence for effects of single genetic markers. Highly powered multimodal brain- and disorder-related genome-wide studies are needed to further dissect the shared genetic influences on brain structure and risk for AN

    Comparação entre métodos de determinação da biomassa microbiana baseados no princípio da fumigação e extração.

    Get PDF
    We report measurement of the cross section of e+eπ+πψ(2S)e^+e^-\to \pi^+\pi^-\psi(2S) between 4.0 and 5.5GeV5.5 {\rm GeV}, based on an analysis of initial state radiation events in a 980fb1980 \rm fb^{-1} data sample recorded with the Belle detector. The properties of the Y(4360)Y(4360) and Y(4660)Y(4660) states are determined. Fitting the mass spectrum of π+πψ(2S)\pi^+\pi^-\psi(2S) with two coherent Breit-Wigner functions, we find two solutions with identical mass and width but different couplings to electron-positron pairs: MY(4360)=(4347±6±3)MeV/c2M_{Y(4360)} = (4347\pm 6\pm 3) {\rm MeV}/c^2, ΓY(4360)=(103±9±5)MeV\Gamma_{Y(4360)} = (103\pm 9\pm 5) {\rm MeV}, MY(4660)=(4652±10±8)MeV/c2M_{Y(4660)} = (4652\pm10\pm 8) {\rm MeV}/c^2, ΓY(4660)=(68±11±1)MeV\Gamma_{Y(4660)} = (68\pm 11\pm 1) \rm MeV; and B[Y(4360)π+πψ(2S)]ΓY(4360)e+e=(10.9±0.6±0.7)eV{\cal{B}}[Y(4360)\to \pi^+\pi^-\psi(2S)]\cdot \Gamma_{Y(4360)}^{e^+e^-} = (10.9\pm 0.6\pm 0.7) \rm eV and B[Y(4660)π+πψ(2S)]ΓY(4660)e+e=(8.1±1.1±0.5)eV{\cal{B}}[Y(4660)\to \pi^+\pi^-\psi(2S)]\cdot \Gamma_{Y(4660)}^{e^+e^-} = (8.1\pm 1.1\pm 0.5) \rm eV for one solution; or B[Y(4360)π+πψ(2S)]ΓY(4360)e+e=(9.2±0.6±0.6)eV{\cal{B}}[Y(4360)\to \pi^+\pi^-\psi(2S)]\cdot \Gamma_{Y(4360)}^{e^+e^-} = (9.2\pm 0.6\pm 0.6) \rm eV and B[Y(4660)π+πψ(2S)]ΓY(4660)e+e=(2.0±0.3±0.2)eV{\cal{B}}[Y(4660)\to \pi^+\pi^-\psi(2S)]\cdot \Gamma_{Y(4660)}^{e^+e^-} = (2.0\pm 0.3\pm 0.2) \rm eV for the other. Here, the first errors are statistical and the second systematic. Evidence for a charged charmoniumlike structure at 4.05GeV/c24.05 {\rm GeV}/c^2 is observed in the π±ψ(2S)\pi^{\pm}\psi(2S) intermediate state in the Y(4360)Y(4360) decays.Comment: 21 pages, 12 figure

    Synaptic AMPA receptor composition in development, plasticity and disease

    Full text link
    corecore